PADI4 promotes epithelial-mesenchymal transition (EMT) in gastric cancer via the upregulation of interleukin 8

Xiao-tian Chang1,2, Hui Wu3, Hui-lin Li3, Hong-lei Li1 and Ya-bing Zheng1*

Abstract
Background: Gastric cancer (GC) is one of the deadliest tumours due to its ability to metastasize. The Epithelial–to-mesenchymal transition plays a crucial role in promoting the GC metastasis, which increases the migration and metastasis of tumour cells. Peptidyl arginine deiminase IV (PADI4) is a susceptibility gene for gastric carcinoma. The aim of this study was to evaluate the functional roles of PADI4 in gastric cancer.

Methods: The expression of PADI4 was examined by qRT-PCR, western blot and immunohistochemistry. In addition, the functional roles of PADI4 were explored by over-expression PADI4 plasmids in gastric cancer cells.

Results: We found that the expression of PADI4 was up-regulated in GC. PADI4 overexpression in GC cells increased the proliferation, migration, metastasis, clone forming ability, and tumorigenic ability, but reduced the apoptosis ability. The Multi-Analyte ELISArray Kit results showed that interleukin 8 (IL-8) is upregulated in PADI4-overexpressing gastric cells. Using short interfering RNA (siRNA) to silence the expression of IL-8, we demonstrated that IL-8 silencing significantly inhibited the increased migratory capacity in PADI4-overexpressing GC cells.

Conclusions: Our data suggest that PADI4 accelerate metastasis by promoting IL-8 expression in gastric cancer cells, indicating that it is a new PADI4/IL-8 signalling pathway in metastatic GC.

Keywords: Gastric cancer, Metastasis, EMT, Peptidyl arginine deiminase IV, Signaling pathway

Background
Gastric cancer (GC) is a common cancer in the world [1]. This disease is mostly diagnosed at the late stage and accompanied by metastasis [2]. The current treatment for metastatic GC is limited and ineffective. The median overall survival of metastatic GC ranges from 9 to 13 months despite treatment with systemic chemotherapy [3]. Metastasis is the main cause of death in GC. Therefore, it is essential to understand the pathogenesis of GC metastasis, which will help us to find more approaches for the treatment of metastatic GC. Recent studies have found that epithelial-mesenchymal transition (EMT) play an important role in provide cancer cells with mobility [4]. The EMT is the process by lose their epithelial characteristics and acquire migratory and invasive properties characteristic of cancer cells [5]. This process is accompanied by decreased expression of epithelial markers (E-cadherin) and increased expression of mesenchymal markers (neural cadherin and vimentin). A group of paracrine factors, including Snail family and zinc-finger transcription factors, promote the expression of EMT at the translational and posttranslational levels [6]. Therefore, it is very important to explore...
the mechanism of EMT in the pathogenesis of gastric cancer.

Peptidyl arginine deiminase IV (PADI4) is a calcium-dependent enzyme, and its role is to convert arginine to citrulline [7]. Citrullination mediated by peptidyl arginine deaminase plays a major role in the functional and structural stability of proteins and then affects the physiological and pathological processes of the body [8]. Increasing evidence suggests that PADI4 is involved in tumour progression [9]. We and others have found that PADI4 is overexpressed in many cancers, including ovarian cancer, colorectal cancer, lung cancer, cervical squamous cell carcinoma and thyroid carcinoma [10]. The pathological classification of oesophageal squamous cell carcinoma was positively correlated with the expression level of PADI4 [7, 11]. Moreover, it has been reported that PADI4 plays a crucial function in tumour cell proliferation, apoptosis and EMT [12]. We have reported that PADI4 can increase ovarian cancer cell line A280 proliferation, invasion and migration via the p53 signalling pathway [13]. In addition, we have reported that PADI4 is a susceptibility gene for GC. PADI4 upregulates the expression levels of KRT14, CXCR2 and TNF-α, which are related to cell proliferation, cell migration, tumour angiogenesis, and tumour immune microenvironment [14]. However, the role of PADI4 in the development of GC, especially in gastric metastases, is poorly understood.

Interleukin-8 (IL-8, also called CXCL8) is a cytokine of the CXC chemokine family that is believed to be related to cancer development and chronic inflammation [15]. IL-8 can activate cell surface G protein-coupled receptors (CXCR1 and CXCR2) in various signalling pathways [16]. As a very important autocrine regulator factor in the tumour microenvironment, IL-8 and/or its receptors play a crucial role in regulating tumour growth and metastasis, especially in human gastric carcinoma cells [17, 18]. Overexpression of IL-8 promotes cellular proliferation, metastasis, invasion, adhesion in GC cells [16]. Fu et al. found that IL-8 is involved in the EMT process [19].

In this study, we found that PADI4 can promoted the proliferation, migration and inhibited the apoptosis of GC cells. Further studies showed that these functions are achieved by controlling the expression of IL-8. Those results of this study provide a new mechanism for the role of PADI4 in GC metastasis and provide a reasonable explanation for the correlation between the high expression of PADI4 and clinical stage of gastric cancer, suggesting that PADI4 may become a potential therapeutic target for advanced gastric cancer.

| Table 1 | List of primers used for quantitative PCR |
|---------|-----------------------------------------|
| Primer  | Sequence(5’–3’)                          |
| PADI4-Forward | 5’-GGG GTG GTG GAT ATT GC-3’          |
| PADI4-Reverse | 5’-CCC GGT GAG GTA GAG TAG AGC-3’   |
| GAPDH-Forward | 5’-CAGAACATCATCCTGCCCCTCTAC-3’  |
| GAPDH-Reverse | 5’-TTGAAGTCAAGGAGACCACCTG-3’ |

Methods

Tissue collection
Tumour tissues(n = 7) and normal adjacent mucosal tissues(n = 7) were collected from 30 to 70 years old from April 2017 to June 2019 at Shandong Province Qianfoshan Hospital. The distance between the tumour tissues and normal adjacent mucosal tissues was 5 cm. The inclusion and exclusion criteria for the patients were based on the method of Wang B et al. [20].

Written informed consent was obtained from each participating individual, our study was approved by the Ethics Committee of Shandong Provincial Qianfoshan Hospital, all methods were performed in accordance with the International Conference on Harmonization Guideline for Good Clinical Practice (E6) and the 2013 Declaration of Helsinki. Tumour diagnosis performed according to the World Health Organization(WHO) classification system.

Western blotting
Total protein was lysed from GC tissues or cells by using RIPA lysis solution (Solarbio, China). Thirty micrograms of total protein extract was separated by 10% SDS-PAGE and then transferred to a PVDF membrane, the PVDF membrane was then incubated with 5% skim milk for 1 h. Following being incubated with primary antibodies (1:1,000) overnight at 4 °C. Then washed three times, the membrane was incubated with HRP-conjugated secondary antibody (1:5,000) for 1 h. The signal was detected using enhanced chemiluminescence (ECL) with an Alpha FluorChem E (Cell Biosciences, USA). The primary antibodies targeting PADI4 (ab128086; Abcam); GAPDH (ab181603; Abcam); CXCL8 (DF6998; Affinity); vimentin (cat. no. 5741; Cell Signaling Technology) and E-cadherin (cat. no. 3195; Cell Signaling Technology) were used in this study.

Real-time PCR
Total RNA was isolated from GC tissues or cells(Invitrogen, USA). One microgram of total RNA was reverse transcribed into first-strand cDNA (Vazyme, China), which was then used as the PCR template.
Real-time PCR was performed using Bio-Rad CFX96 detection system. The primers were listed in Table 1. Data were analysed by the formula: $R = 2^{-\Delta\Delta C_t}$.

Immunohistochemistry

GC tissue array was obtained commercially from Alena-bio (cat. no. ST242). The array slides contained 20 gastric cancer and 4 normal tissue samples. The tissue sections were deparaffinized and rehydrated by standard procedures. After antigen retrieval and incubation with an endogenous peroxidase inhibitor (Maixin, China), the array slides were incubated with the anti-PADI4 antibody overnight. Then, the tissue array were incubated with secondary antibody (1:500; cat. no. A0216; Beyotime) for 30 min. The slides were then stained with haematoxylin. The result of the IHC for PADI4 was judged based on Liu H et al. method [21].

Cell culture

The human GC cell lines(SGC-7901, MGC80-3) were obtained from GeneChem. SGC-7901 is a moderately differentiated cell originating from lymph node metastases with gastric adenocarcinoma. MGC80-3 is a poorly differentiated cell with gastric mucoid adenocarcinoma. SGC-7901 and MGC80-3 cells were cultured in DMEM (Gibco) containing 10% foetal bovine serum (Gibco). Cells were maintained in a humidified atmosphere containing 5% CO₂ at 37 °C and passaged once every two days.

Plasmid construction and transfection

The pcDNA 3.1(+)‐RFP containing the full sequence of PADI4 was applied to overexpress PADI4. The pcDNA 3.1(+)‐RFP or pcDNA 3.1(+)‐PADI4‐RFP plasmid were transfected into GC cells using PolyJet™ transfection reagent (SignaGen, USA) in accordance with the manufacturer’s protocol. Cells transfected with pcDNA 3.1(+)‐RFP were used as negative controls. The transfected cells were then harvested for 48 h for further experiments.

Wound-healing assay

After transfection, cells were plated into 6-well plates. After the cells reached 100% confluence, a scratch was made by a pipette tip, and a photo was taken at 0 and 24 h. Wound healing was imaged under the microscope.

Transwell migration assay

GC cells after transfection in six plates for 24 h. Then, the upper chambers (3412; Corning) were added with serum-free culture medium containing $1 \times 10^5$ transfected cells. After cultured for 24 h, cells were immersed in methanol and stained with 600 µl 1% crystal violet. The cells were counted with the microscope.

Cell proliferation

Cell Counting Kit 8 (CCK-8) (Dojindo, Japan) assays were performed to assess cell proliferation. Cultured cells were cultured in 96-well plates with the initial density of 5,000 cells/well. The cells were transfected with pcDNA 3.1(+)‐RFP or pcDNA 3.1(+)‐PADI4‐RFP as described above. At 24 h, 48 h after transfection, CCK-8 was added into the cell culture medium. The absorbance was determined at 450 nm using SpectraMax 190 (Molecular Device).

Colony formation assay

One thousand GC cells were transfected with pcDNA 3.1(+)‐RFP or pcDNA 3.1(+)‐PADI4‐RFP as described above after being seeded in 60 mm cell culture dishes. Then, the cells were incubated for two weeks until colonies appeared. After being fixed with methanol and stained using 1% crystal violet for 30 min, the colonies (each colony with at least 50 cells) were counted.

Cell apoptosis assay

GC cells after transfection in six plates for 48 h, and then washed and resuspended. The cell suspensions were transferred into tubes, and 1.5 µl of crystal violet (eBioscience; USA) was added for 30 min. Then, 5 µl of fluorescein isothiocyanate (FITC) (eBioscience; USA) were added to the tube for 15 min in the dark.

Xenograft model

Male nude mice (5 weeks; 17–18 g) were housed in a pathogen-free animal facility. All procedures were approved by the Committee for Animal Research at Shandong Provincial Qianfoshan Hospital, and were performed according to the guidelines for animal care and use. The pHBLV-CMV-6*His-EF1-mCherry-puro lentiviral vector containing full coding sequence of PADI4 was applied to overexpress PADI4 (Hanbio, China). Recombinant pHBLV-CMV-PADI4-6*His-EF1-mCherry-puro viruses were transfected into MGC80-3 cells (1*10⁷/ml) injected into the left flank of each mouse to generate tumour-bearing BALB/c nude mice; pHBLV-CMV-6*His-EF1-mCherry-puro viruses were transfected into MGC80-3 cells as the control group and injected into the right flank of each mouse (n = 8). Tumours were dissected 40 days after cell injection, and the size and weight of the tumours were measured by routine methods.

Multi-analyte ELISArray and ELISA analyses

GC cells after transfection in six plates for 48 h, the Multi-Analyte ELISArray Kit(cat. no. MEM-004A)
Qiagen, USA) were used to screen cytokines performed the manufacturer’s instructions. This kit can measure the levels of IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17A, interferon-γ(IFN-γ), tumour necrosis factor-α(TNF-α) and granulocyte–macrophage colony-stimulating factor (GM-CSF). The absorbance levels of these cytokines were measured on a plate reader (SpectraMax 190, Molecular Device) at 450 nm. We tested the expression level of IL-8 by ELISA analyses.

**siRNA transfection**

Anti-IL-8 siRNA (target mRNA sequence: 5’-GCAGAA GGUUGUACAGAUATT-3’) and nonsilencing siRNA (sequence 5’-UUCUUCGAA CGUGUCACGUTT-3’) were synthesized by GenePharma Co. Ltd. The cultured GC cells were transfected with the anti-IL-8 siRNA or anti-PADI4 siRNA using PepMute™ siRNA transfection reagent(SignaGen, USA) according to the manufacturer’s instructions.

**Statistical analysis**

Data are presented for experiments performed in triplicate and are expressed as mean ± standard deviation(SD). SPSS 19.0 software was used for the experimental data analysis. Statistical analysis was performed with Student’s
t-test between two groups or one-way ANOVA for multiple groups. *$p<0.05$, **$p<0.01$, ***$p<0.001$.

**Ethics approval**

This study was approved by the Ethics Committee of Shandong Provincial Qianfoshan Hospital with the number of 2017(S090). All methods were performed in accordance with the relevant guidelines and regulations.

**Results**

**PADI4 is overexpressed in GC tissues**

Analysis of tissues revealed that PADI4 protein expression levels in GC tissue tumour samples were increased compared with those in the corresponding adjacent tissues ($p = 0.03$; Fig. 1A, B). Similarly, PADI4 mRNA expression measured by real-time PCR was also significantly increased in GC tumour samples compared with...
paired adjacent normal gastric tissue samples \( (p = 0.002; \text{Fig. 1C}) \).

We detected the expression of PADI4 in GC tissues by immunohistochemistry. The results showed that PADI4 was positive in GC tissues, such as nasointestinal tube and mucinous cystadenocarcinoma of GC patients but was limited in normal gastric tissues (Fig. 1D, E).

**Effect of PADI4 on GC cell migration, proliferation, colony formation and apoptosis**

GC cells were transfected with recombinant pcDNA3.1-RFP-PADI4 plasmid or pcDNA3.1-RFP plasmid. Western blot results found the increased expression of PADI4 (Fig. 2A). Therefore, the pcDNA3.1-RFP-PADI4 plasmid was used for further studies.

![Fig. 3](image-url)
The role of PADI4 expression in the cell migration ability was investigated by wound healing assay and Transwell migration assay. The wound healing assay showed that the PADI4-transfected GC cells had a significantly higher migration rate (SGC-7901, \( P = 0.021 \); MGC80-3, \( P = 0.006 \)) (Fig. 2D, E). In addition, Transwell migration assay exhibited that the PADI4-transfected SGC-7901 and MGC80-3 cells had 1.78- and 1.4-fold higher migration than that observed in the empty vector cells (SGC-7901, \( P = 2.7 \times 10^{-5} \); MGC80-3, \( P = 0.004 \)) (Fig. 2F, G). Moreover, PADI4 overexpression decreased expression of E-cadherin and increased expression levels of Slug and vimentin (\( P < 0.05 \); Fig. 2A–C). Hence, these results demonstrated that PADI4 can promote cell migration in vitro.

The proliferation of GC cells was measured using CCK-8 and colony formation assays. We found that overexpression of PADI4 significantly increased the proliferation of GC cells at 24 h, 48 h and 72 h, indicating that PADI4 expression significantly increased the proliferation of GC cells (\( P < 0.05 \); Fig. 3A, B). Colony formation assays demonstrated that overexpression of PADI4 increased the number of colonies in GC cells (SGC-7901, \( P = 0.002 \); MGC80-3, \( P = 3.6 \times 10^{-5} \)) (Fig. 3C, D). These
results indicate that PADI4 contributes GC cell proliferation and colony formation ability in vitro.

Flow cytometric analysis was used to measure the effects of PADI4 on GC cells apoptosis ability. The proportion of apoptosis was significantly decreased in GC cells transfected with pcDNA3.1-RFP-PADI4 plasmid compared with the cells treated with pcDNA3.1-RFP plasmid (SGC-7901, \( P = 0.014 \); MGC80-3, \( P = 0.006 \)) (Fig. 3E, F).

**PADI4 promotes the growth of GC tumors in vivo**

To confirm the role of PADI4 in GC in vivo conditions, we made a xenograft tumor model by subcutaneously injecting MGC80-3 cells stably over-expressing PADI4, the results showed that the average tumor weight in mice injected with PADI4-overexpressing virus transfected MGC80-3 cells was 534.7 mg, while the tumor weight of the control group was 320.7 mg (\( P = 0.012 \); Fig. 4A–D). These results demonstrate that increasing the expression of PADI4 can significantly accelerate cell activity and tumor growth in vivo. Additionally, our real-time PCR showed that tumors in mice injected with PADI4-overexpressing MGC80-3 cells exhibited strong PADI4 expression (\( P = 4.4 \times 10^{-8} \); Fig. 4E). These results indicate that PADI4 can promote GC tumor growth in vivo.

**PADI4 regulates IL-8 expression**

To better understand the mechanism of PADI4 involved in the progression of chronic inflammation in GC. We used a Multi-Analyte ELISA Array Kit to screen cytokines in GC cell culture medium, and the results showed that PADI4-transfected GC cells produced a higher level of IL-1\( \alpha \), IL-6 and IL-8 compared with empty vector cells, but undetectable levels of release of cytokines IL-1\( \beta \), IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-17A and GM-CSF in GC cell culture supernatants (Fig. 5A). To verify the above results, we performed ELISA and western blotting experiments, and the results showed that the GC cells transfected with the pcDNA3.1-PADI4-RFP plasmid produced a higher level of IL-8 than empty vector cells (\( P < 0.05 \); Fig. 2A and 5B). Next, siRNA against PADI4 was transfected to GC cells to reduce PADI4 expression. We also found that the expression of IL-8 protein in PADI4 knockdown GC cells was downregulated (\( P < 0.05 \); Fig. 5C, D).
Fig. 5C, D). These data suggest that PADI4 regulates the expression of IL-8 protein.

**IL-8 knock-down reversed the effects of PADI4 on GC cells EMT and migration**

We all know that IL-8 plays a vital role during the process of EMT [16], and we have found that PADI4 can regulate the expression of IL-8 and participate in the EMT process of gastric cancer (Figs. 2 and 5). This evidence prompted us to hypothesize that PADI4 regulates EMT function possibly by regulating the expression of IL-8 in GC. Thus, siRNAs targeting IL-8 were used in PADI4-overexpressing GC cells.

We found that silencing IL-8 significantly decreased the levels of IL-8 and vimentin in GC cells compared with nonsilencing siRNA GC cells (P < 0.05; Fig. 6). Moreover, Transwell results showed that silencing IL-8 expression significantly inhibited the increased metastatic capacity in PADI4-overexpressing GC cells (P < 0.05; Fig. 7).

**Discussion**

GC has the characteristics of high incidence rate, high mortality rate and poor prognosis [22]. The reason for the high mortality is that most patients with GC have an advanced stage or metastasis, thus losing the best opportunity for treatment [23]. Although the surgical success rate and postoperative survival rate for tumours have been significantly improved at present, metastatic cancer patients still have higher drug resistance, poor treatment effect and low survival rate [24]. Therefore, the treatment of gastric cancer is still a high challenge.

PADI4 can generate of citrullinated proteins through convert peptidylarginine to peptidylcitrulline in the presence of Ca^{2+} [12], leading to the change of protein conformation and biochemical activity [25]. In rheumatoid arthritis (RA), PADI4 increases thrombin activity by citrullinating antithrombin, and thereby affects the vascular endothelial cells proliferation and RA synovial tissue inflammation [26, 27]. PADI4 also plays an important role in tumorigenesis and pathogenesis in lung cancer,
colorectal cancer, oesophageal cancer and ovarian carcinoma [7, 13, 28, 29].

In this study, we found the expression of PADI4 was elevated in GC tissues. PADI4 play importance roles in regulating the cell proliferation, migration, colony formation capabilities and apoptosis capability of different degrees of differentiated cells. PADI4 also can accelerates cell activity and tumour growth in tumour-bearing tissues in vivo. This is consistent with the role of PADI4 in other cancers. Therefore, PADI4 has an oncogenic role in GC and can be a prognostic indicator of GC.

PADI4 have been reported play an important role in the pathogenesis of lung cancer by mediating EMT [30, 31]. The characteristic of EMT is that it loses the adhesion ability of tumour epithelial cells and obtains the migration ability of mesenchymal cells, resulting in increased metastasis and drug resistance [5]. EMT plays a vital role in tumour metastasis. Our study found that the overexpression of PADI4 increased the migration ability of GC cells, increased the expression of the EMT markers vimentin and slug, but decreased E-cadherin expression. Those results suggest that PADI4 promotes cell migration in GC through EMT process. This is the first report to
demonstrate a new role of PADI4 in EMT and cell metastasis in GC.

To clarify the molecular mechanism of PADI4 in GC progression, we used the Multi-Analyte ELISAArray Kit to analyse the expression of cytokines in PADI4-transfected GC cells. In the Multi-Analyte ELISAArray Kit results, IL-8 was upregulated in PADI4-overexpressing SGC-7901 and MGC80-3 cells. IL-8 is a chemokine that can stimulate the migration of leucocytes. In ovarian cancer, IL-8 can promote migration and EMT through Wnt/β-catenin signalling network [32]. Evidences shows that IL-8 involved in promoting migration of colon cancer, pancreatic cancer and other types of cancers [18, 33–35]. Meanwhile, the level of IL-8 has been proven to be an indicator of poor prognosis in GC [36]. However, the pathogenesis of IL-8 in GC remains unclear. In this study, we found that silencing IL-8 expression blocked the expression of the EMT marker vimentin in PADI4-overexpressing GC cells. Transwell assays also showed that IL-8 silencing significantly inhibited the increased migration ability of PADI4 overexpressing GC cells. PADI4 is markedly upregulated in GC tissues. Thus, this study indicates that PADI4 promotes GC cells migration and EMT progression by regulating the expression of IL-8. These findings reveal a key role of the PADI4/IL-8 signalling pathway in EMT and provide a possible molecular mechanism for gastric carcinogenesis.

Conclusions
Based on our findings, this study demonstrated that PADI4 could promote cell proliferation, migration and colony formation capabilities and inhibit the apoptosis in GC cells. The migration of GC cells caused by PADI4 was reduced by interference with IL-8 expression. We suggest that PADI4 can accelerate GC migration mediated by IL-8. Therefore, PADI4 has an oncogenic role in GC and could be a new target for GC diagnosis and therapy.

Abbreviations
GC: Gastric cancer; EMT: Epithelial–mesenchymal transition; PADI4: Peptidyl arginine deiminase IV; IL-8: Interleukin 8; siRNA: Small interfering RNA; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; SDS-PAGE: Sodium dodecyl sulfate–polyacrylamide gel electrophoresis; PVDF: Polyvinylidene fluoride; TBS: Tris-buffered saline; HRP: Horseradish peroxidase; ECL: Enhanced chemiluminescence; CCK-8: Cell Counting Kit-8; FITC: Fluorescein isothiocyanate; IFN: Interferon; TNF: Tumour necrosis factor; GM-CSF: Granulocyte–macrophage colony-stimulating factor; SEs: Standard errors.

Acknowledgements
Not applicable.

Arrive guidelines statement
The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Authors’ contributions
Xiaotian Chang and Yabing Zheng designed the experiment and wrote the manuscript. Huilin Li and Hongjie Li analysed the data. Hui Wu and Yabing Zheng performed the experiment, and Xiaotian Chang and Yabing Zheng provided funding. All authors read and approved the final manuscript.

Funding
This study was supported by Shandong Provincial Key R&D Program, Grant/Award Number: 2017GSF218102.

Availability of data and materials
The data are available from the corresponding author upon request.

Declarations

Ethics approval and consent to participate
The BALB/c nude mice used in this study were housed in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility. The use of clinical samples was approved by the ethics committee of Shandong Provincial Qianfoshan Hospital. Informed consent was obtained from all patients. The study was approved by the Ethics Committee of Shandong Provincial Qianfoshan Hospital, Jinan, China.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan 250014, Shandong, China. 2 Medical Research Center of The Affiliated Hospital of Qingdao University, and Qingdao Engineering Laboratory of Rheumatic Disease and Translational Medicine, Shandong Key Laboratory of Clinical Medicine, Qingdao 266000, Shandong, China. 3 Shandong Provincial Qianfoshan Hospital, Jinan 250014, Shandong, China.

Received: 9 September 2021   Accepted: 3 January 2022
Published online: 19 January 2022

References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
2. Zhou X, Yin C, Dang Y, Ye F, Zhang G. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep. 2015;5:11156.
3. Schmidt T, Alldinger I, Blank S, Klose J, Springfeld C, Dreikhausen L, Weichert W, Grenacher L, Bruckner T, Lordick F, et al. Surgery in oesophageo-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. Eur J Surg Oncol. 2015;41(10):1340–7.
4. Foroni C, Brogini M, Generali D, Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev. 2012;38(6):689–97.
5. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 2012;72(19):4883–9.
6. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16(6):488–94.
7. Liu C, Tang J, Li C, Pu G, Yang D, Chang X. PADI4 stimulates esophageal squamous cell carcinoma tumor growth and up-regulates CA9 expression. Mol Carcinog. 2019;58(1):66–75.
8. Chavanas S, Mechlin MC, Nachat R, Adoue V, Coudane F, Serre G, Simon M. Peptidylarginine deiminases and deamination in biology and pathology: relevance to skin homeostasis. J Dermatol Sci. 2006;44(2):63–72.
9. Kolodziej S, Kuvardina ON, Oellerich T, Herglotz J, Backert I, Kohrs N, Buscato E, Wittmann SK, Salinas-Riesto G, Benig H, et al. PAD4 acts as a coactivator of TFα by countering repressive histone arginine methylation. Nat Commun. 2014;5:3995.

10. Chang X, Hou X, Pan J, Fang K, Wang L, Han J. Investigating the pathogenic role of PAD4 in oesophageal cancer. Int J Biol Sci. 2011;7(6):769–81.

11. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z. Increased PAD4 expression in blood and tissues of patients with malignant tumors. BMC Cancer. 2009;9:40.

12. Stadler SC, Vincent CT, Fedorov VD, Patsialou A, Cherrington BD, Wakshlag JJ, Mohan S, Zee BM, Zhang X, Garcia BA, et al. Dysregulation of PAD4-mediated citrullination of nuclear GSK3β activates TGF-β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. Proc Natl Acad Sci U S A. 2013;110(29):11851–6.

13. Cui YY, Lan L, Zhou J, Zhao S, Zheng YB, Sun BH, Lv HT, Rong FN, Chang XT. The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion. Tumour Biol. 2016;37(4):5375–83.

14. Zheng Y, Zhao G, Xu B, Liu C, Li C, Zhang X, Chang X. PAD4 has genetic susceptibility to gastric carcinoma and upregulates CXCR2, KRT14 and TNF-alpha expression levels. Oncotarget. 2016;7(38):62159–76.

15. Bie Y, Ge W, Yang Z, Cheng X, Zhao Z, Li S, Wang W, Wang Y, Zhao X, Yin Z, et al. The crucial role of CXCL13 and its receptors in colorectal liver metastasis. Dis Markers. 2019;2019:8023460.

16. Kuai WX, Wang Q, Yang XZ, Zhao Y, Yu R, Tang XJ. Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of gastric cancer cells. World J Gastroenterol. 2012;18(9):979–85.

17. Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, Yamamoto S, Sumii K, Kajiyama G, Fidler IJ, et al. Regulation of disease-progression genes in human gastric cancer cells by interleukin 8. Clin Cancer Res. 2000;6(7):2735–40.

18. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735–41.

19. Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ, Zhou SL, Zhao YM, Xiao YS, Sun QM, Ding ZB, et al. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int J Oncol. 2015;46(2):587–96.

20. Wang B, Jiang H, Wan X, Wang Y, Zheng X, Li P, Guo J, Ding X, Song H. Carboxic anhydrase IV inhibits cell proliferation in gastric cancer by regulating the cell cycle. Oncol Lett. 2020;20(4):4.

21. Liu H, Liu N, Zhao Y, Zhu X, Wang C, Liu Q, Gao C, Zhao X, Li J. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling. Aging (Albany NY). 2019;11(21):9643–60.

22. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

23. Zhao J, Liu Y, Zhang W, Zhou Z, Wu J, Cui P, Zhang Y, Huang G. Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer. Cell Cycle. 2015;14(19):3112–23.

24. Feng W, Ding Y, Zong W, Ju S. Non-coding RNAs in regulating gastric cancer metastasis. Clin Chim Acta. 2019;496:125–33.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.